Comparative validity of depression assessment scales for screening poststroke depression

详细信息    查看全文

• 作者：Hee-Ju Kang^a ; Robert Stewart^b ; Jae-Min Kim^a ; ^{jmkim@chonnam.ac.kr} ; Ji-Eun Jang^a ; Seon-Young Kim^a ; Kyung-Yeol Bae^a ; Sung-Wan Kim^a ; Il-Seon Shin^a ; Man-Seok Park^c ; Ki-Hyun Cho^c ; Jin-Sang Yoon^a
• 关键词：Poststroke depression ; Assessment scale ; Screening test ; Validity ; Longitudinal study
• 刊名：Journal of Affective Disorders
• 出版年：2013
• 出版时间：May, 2013
• 年：2013
• 卷：147
• 期：1-3
• 页码：186-191
• 全文大小：176 K

文摘

Introduction

This study aimed to compare screening properties of four assessment scales for poststroke depression (PSD) at 2 weeks and 1 year after index stroke, and investigated factors contributing to misclassification.

Methods

A total of 423 patients were evaluated 2 weeks after stroke and 288 (68 % ) were followed 1 year later, and were diagnosed as having major and minor PSD applying DSM-IV criteria gold standards. The Beck Depression Inventory (BDI), Hospital Anxiety and Depression Scale-depression subscale (HADS-D), Hamilton Rating Scale for Depression (HAMD), and Montgomery-Asberg Depression Rating Scale (MADRS) were administered. The balance of sensitivity and specificity was assessed using receiver operating characteristics (ROC) analysis.

Results

Discriminating abilities of all the scales for major and all PSD were good (area under ROC values 0.88-0.93 and 0.88-0.92 at 2 weeks; and 0.93-0.96 and 0.89-0.91 at 1 year, respectively). Misclassification was influenced by demographic characteristics and stroke severity particularly for the BDI and HAMD, was more marked for all PSD than for major PSD, and was more prominent at 2 weeks than at 1 year after stroke.

Limitations

Patients with only mild to moderate stroke severity were included.

Conclusions

Although there were no marked differences in the screening abilities for PSD between the scales, differences were found in factors influencing misclassification. Assessment scales with less somatic items may be recommended for the screening of PSD, particularly at the acute phase of stroke.